BR112012033212A2 - uso de lactobacillo inibindo a produção de gás de bactéria coliforme isolada em infantes afetados por cólica - Google Patents

uso de lactobacillo inibindo a produção de gás de bactéria coliforme isolada em infantes afetados por cólica

Info

Publication number
BR112012033212A2
BR112012033212A2 BR112012033212A BR112012033212A BR112012033212A2 BR 112012033212 A2 BR112012033212 A2 BR 112012033212A2 BR 112012033212 A BR112012033212 A BR 112012033212A BR 112012033212 A BR112012033212 A BR 112012033212A BR 112012033212 A2 BR112012033212 A2 BR 112012033212A2
Authority
BR
Brazil
Prior art keywords
colic
lactobacillo
affected infants
coliform bacteria
gas production
Prior art date
Application number
BR112012033212A
Other languages
English (en)
Other versions
BR112012033212B1 (pt
Inventor
Gianna Scatizzi
Original Assignee
Probiotical Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiotical Spa filed Critical Probiotical Spa
Publication of BR112012033212A2 publication Critical patent/BR112012033212A2/pt
Publication of BR112012033212B1 publication Critical patent/BR112012033212B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

uso de lactobacillo inibindo a produção9 de gás de bactéria coliforme isolada em infantes afetados por cólica. a presente invenção refere-se a uma composição compreendendo duas cepas probióticas de bactéria capazes de realizar uma ação competitiva e antibacteriana e/ou antioxidante contra espécies de bactérias coliformes que produzem gás por fermentação de açúcar, em particular lactose, isolada em infantes afetados por cólica.
BR112012033212-0A 2010-06-28 2010-06-28 composição de cepa probiótica que inibe a produção de gás de bactéria coliforme isolada em infantes afetados por cólica, sendo utilizada como composição alimentar, suplemento ou composição farmacêutica BR112012033212B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2010/001554 WO2012001440A1 (en) 2010-06-28 2010-06-28 Use of lactobacilli inhibiting gas producing coliform bacteria isolated from infants affected by colic

Publications (2)

Publication Number Publication Date
BR112012033212A2 true BR112012033212A2 (pt) 2016-10-25
BR112012033212B1 BR112012033212B1 (pt) 2021-06-08

Family

ID=42989661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012033212-0A BR112012033212B1 (pt) 2010-06-28 2010-06-28 composição de cepa probiótica que inibe a produção de gás de bactéria coliforme isolada em infantes afetados por cólica, sendo utilizada como composição alimentar, suplemento ou composição farmacêutica

Country Status (11)

Country Link
US (1) US9255246B2 (pt)
EP (1) EP2585085B1 (pt)
JP (1) JP2013531506A (pt)
CN (1) CN103079580B (pt)
BR (1) BR112012033212B1 (pt)
DK (1) DK2585085T3 (pt)
ES (1) ES2491619T3 (pt)
PL (1) PL2585085T3 (pt)
RU (1) RU2544054C2 (pt)
UA (1) UA107711C2 (pt)
WO (1) WO2012001440A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1403661B1 (it) 2011-01-28 2013-10-31 Probiotical Spa Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
ITMI20110679A1 (it) * 2011-04-20 2012-10-21 Giovanni Mogna Composizione comprendente batteri probiotici in grado di ripristinare l effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell iperacidita gastrica.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITRM20110477A1 (it) 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
ITRM20110475A1 (it) * 2011-09-09 2013-03-10 Probiotical Spa Ceppi di batteri lattici e/o bifido batteri, opzionalmente addizionati di n-acetilcisteina e/o lisozima microincapsulato gastroprotetto, aventi attivita' di inibizione/riduzione della crescita di differenti biotipi di e.coli, incluso e.coli o157:h7 e
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
ITMI20130793A1 (it) 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
WO2015148943A1 (en) * 2014-03-28 2015-10-01 Conjugon, Inc. Preparation of small colony variants of therapeutic bacteria
EP3294308A4 (en) 2015-05-14 2019-03-06 University of Puerto Rico PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN
CN114647779A (zh) * 2015-08-12 2022-06-21 爱康迪健康规划服务股份有限公司 信息处理装置、信息处理方法和记录介质
US11564667B2 (en) 2015-12-28 2023-01-31 New York University Device and method of restoring microbiota of newborns
CN108779433A (zh) * 2016-02-12 2018-11-09 波比奥泰克股份公司 属于开菲尔乳杆菌种的细菌菌株在用于产生和/或维持体内稳态状态的儿科学中的应用
ITUB20160708A1 (it) * 2016-02-12 2017-08-12 Probiotical Spa Uso di ceppi di batteri appartenenti alla specie Lactobacillus kefiri in pediatria per generare e/o mantenere lo stato di omeostasi.
KR102135195B1 (ko) * 2018-10-08 2020-07-17 아주대학교산학협력단 테트라제노코커스 할로필러스를 포함하는 베체트병 또는 헤르페스 바이러스 감염증의 예방 또는 치료용 조성물
CN113142396A (zh) * 2021-06-11 2021-07-23 中国农业大学 一种制备豆科牧草青贮饲料用菌剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161422A1 (en) 1999-04-30 2004-08-19 Natarajan Ranganathan Nutritional compositions comprising probiotics
ITMI20020399A1 (it) * 2002-02-28 2003-08-28 Ct Sperimentale Del Latte S P Composizioni dietetiche e/o farmaceutiche per uso umano e/o animale abase di preparati microbici probiotici
CA2503510C (en) * 2002-09-26 2014-12-02 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
US20040185032A1 (en) * 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
JP4387972B2 (ja) * 2005-04-14 2009-12-24 大洋香料株式会社 抗酸化剤
RU2391393C1 (ru) 2008-11-19 2010-06-10 Галина Геннадиевна Алехина ШТАММ Lactobacillus delbrueckii TS1-06, ИСПОЛЬЗУЕМЫЙ ДЛЯ ИЗГОТОВЛЕНИЯ БАКТЕРИАЛЬНЫХ ПРЕПАРАТОВ И ПРОИЗВОДСТВА ЖИДКОЙ МОЛОЧНОКИСЛОЙ ЗАКВАСКИ В КАЧЕСТВЕ ПРОДУКТА ПИТАНИЯ ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКОГО НАЗНАЧЕНИЯ

Also Published As

Publication number Publication date
BR112012033212B1 (pt) 2021-06-08
CN103079580B (zh) 2015-04-29
WO2012001440A1 (en) 2012-01-05
EP2585085B1 (en) 2014-05-28
US20130195823A1 (en) 2013-08-01
UA107711C2 (en) 2015-02-10
US9255246B2 (en) 2016-02-09
CN103079580A (zh) 2013-05-01
JP2013531506A (ja) 2013-08-08
DK2585085T3 (da) 2014-06-23
PL2585085T3 (pl) 2014-10-31
RU2013102424A (ru) 2014-08-10
EP2585085A1 (en) 2013-05-01
ES2491619T3 (es) 2014-09-08
RU2544054C2 (ru) 2015-03-10

Similar Documents

Publication Publication Date Title
BR112012033212A2 (pt) uso de lactobacillo inibindo a produção de gás de bactéria coliforme isolada em infantes afetados por cólica
PH12016501512A1 (en) Treatment for resistant acne
IN2012DN01638A (pt)
MX2021007008A (es) Lisinas de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MX2013005192A (es) Cepa de pasteuria novedosa y usos de la misma.
MX2012012827A (es) Microorganismos y metodos para la biosintesis de butadieno.
MY179664A (en) Microorganisms and methods for the biosynthesis of butadiene
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
MX355955B (es) Efecto antimicrobiano sinergico.
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
EP2558582A4 (en) MICROORGANISMS AND PROCESSES FOR THE PRODUCTION OF ETHYLENE GLYCOL
UA114470C2 (uk) Композиція, що містить антибіотик та диспергатор або антиадгезивний агент
MX2018009553A (es) Metodos de seleccion.
WO2011163500A3 (en) Methods and compositions for reducing body odor
EP2563926A4 (en) MICROORGANISMS AND METHODS OF PROPYLENE BIOSYNTHESIS
MX2011005527A (es) Uso de la bacteria de acido lactico para tratar o prevenir el eczema.
SA113340703B1 (ar) سلالة جديدة من بكتيريا Lactobacillus Crispatus
EA201290623A1 (ru) Лактобациллы с антиоксидантным действием
CL2012002902A1 (es) Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas.
MX356959B (es) Cepa paenibacillus alvei ts-15 y su uso en el control de organismos patogenicos.
GEP20207089B (en) Histamine-producing bacterial strains and their use in cancer
EP3195870A4 (en) Agent for promoting growth of nonpathogenic oral indigenous bacteria or agent for improving oral bacterial flora, and composition for oral use

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2475 DE 12/06/2018 POR TER SIDO INDEVIDA.

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/06/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2728 DE 18-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.